US approves two gene therapies for sickle cell disease

Crispr Therapeutics AG

08/12/2023 16:16

Dec 8 (Reuters) - The U.S. Food and Drug Administration
on Friday approved two gene therapies for sickle cell disease
from Vertex Pharmaceuticals  VRTX.O  and CRISPR Therapeutics
 CRSP.BN , as well as from bluebird bio  BLUE.O .
    Sickle cell disease is a painful, inherited blood disorder
that can be debilitating and lead to premature death. It affects
an estimated 100,000 people in the United States, most of whom
are Black.
  
    

 (Reporting by Sriparna Roy, Leroy Leo and Bhanvi Satija in
Bengaluru;
Editing by Caroline Humer and Bill Berkrot)
 ((Sriparna.Roy@thomsonreuters.com;))